Latest & greatest articles for lung cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on lung cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on lung cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for lung cancer

141. A comparison of prognosis of part-solid and pure-solid tumors in lung cancer: a systematic review and meta-analysis

A comparison of prognosis of part-solid and pure-solid tumors in lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated

2019 PROSPERO

142. Shenqi fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of randomized controlled trials following the PRISMA guidelines

Shenqi fuzheng injection combined with platinum-based chemotherapy for stage III/IV non-small cell lung cancer: a meta-analysis of randomized controlled trials following the PRISMA guidelines Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

143. Association of statins use with lung cancer survival outcomes: a systematic review and meta-analysis

Association of statins use with lung cancer survival outcomes: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files

2019 PROSPERO

144. Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer

Systematic review and meta-analysis of video-assisted thoracoscopic surgery segmentectomy versus lobectomy for stage I non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

145. A systematic review of preclinical and clinical agents evaluated for radiosensitivity for the treatment of lung cancer.

A systematic review of preclinical and clinical agents evaluated for radiosensitivity for the treatment of lung cancer. Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

146. The safety and efficacy of anlotinib versus gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in China: a systematic review and meta-analysis

The safety and efficacy of anlotinib versus gefitinib for patients with advanced non-small cell lung cancer (NSCLC) in China: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

147. The effect of exercise-based interventions on physical function and health-related quality of life in lung cancer survivors: a systematic review and meta-analysis

The effect of exercise-based interventions on physical function and health-related quality of life in lung cancer survivors: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability

2019 PROSPERO

148. A systematic review of Mendelian randomization studies in lung cancer

A systematic review of Mendelian randomization studies in lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation

2019 PROSPERO

149. A systematic review of the prognostic significance of lymph nodal micrometastases in early stage non-small cell lung cancer

A systematic review of the prognostic significance of lymph nodal micrometastases in early stage non-small cell lung cancer Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

150. A critical appraisal of clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II

A critical appraisal of clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

151. Efficacy and acceptability of treatment strategies on EGFR-mutant non-small cell lung cancer patients with brain metastasis: a systematic review and Bayesian network pooled study of survival analysis

Efficacy and acceptability of treatment strategies on EGFR-mutant non-small cell lung cancer patients with brain metastasis: a systematic review and Bayesian network pooled study of survival analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears

2019 PROSPERO

152. Patients involvement in treatment decision-making for early stage non-small cell lung cancer: a qualitative systematic review

Patients involvement in treatment decision-making for early stage non-small cell lung cancer: a qualitative systematic review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

153. A systematic review on oncometabolomics in lung cancers

A systematic review on oncometabolomics in lung cancers Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2019 PROSPERO

154. A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment. Full Text available with Trip Pro

A Model-Based Cost-Effectiveness Analysis of an Exercise Program for Lung Cancer Survivors Following Curative-Intent Treatment. The cost-effectiveness of exercise interventions in lung cancer survivors is unknown. We performed a model-based cost-effectiveness analysis of an exercise intervention in lung cancer survivors.We used Markov modeling to simulate the impact of the Lifestyle Interventions and Independence for Elders (LIFE) exercise intervention compared to usual care for stage I-IIIA (...) lung cancer survivors following curative-intent treatment. We calculated and considered incremental cost-effectiveness ratios (ICERs) <$100,000/quality-adjusted life-year (QALY) as cost-effective and assessed model uncertainty using sensitivity analyses.The base-case model showed that the LIFE exercise program would increase overall cost by $4,740 and effectiveness by 0.06 QALYs compared to usual care and have an ICER of $79,504/QALY. The model was most sensitive to the cost of the exercise program

2019 American journal of physical medicine & rehabilitation Controlled trial quality: uncertain

155. Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. Full Text available with Trip Pro

Lobectomy versus stereotactic ablative radiotherapy for medically operable patients with stage IA non-small cell lung cancer: A virtual randomized phase III trial stratified by age. Although the choice between stereotactic ablative radiotherapy (SABR) and lobectomy for early-stage non-small cell lung cancer (NSCLC) has been debated for years, the two procedures have not yet been directly compared in a randomized trial. We conducted a virtual randomized phase III trial stratified by age (...) no statistically significant difference in the expected overall survival in stage IA NSCLC patients who were older than 75 years and had undergone SABR or lobectomy.© 2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.

2019 Thoracic cancer Controlled trial quality: uncertain

156. The quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II

The quantity and quality of complementary and alternative medicine recommendations in clinical practice guidelines for the treatment or management of lung cancer: systematic review and assessment using AGREE II Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD

2019 PROSPERO

157. Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC)

Alectinib (Alecensa) for the treatment of patients with advanced anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) 1 Cost-effectiveness of alectinib (Alecensa®) for the first line treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung carcinoma (NSCLC) The NCPE has issued a recommendation regarding the cost-effectiveness of alectinib (Alecensa®). Following assessment of the applicant’s submission, the NCPE recommends (...) lymphoma kinase (ALK)-positive advanced non-small cell lung cancer (NSCLC). At the same time, they also converted the conditional marketing authorisation to a standard marketing authorisation for the crizotinib failure indication (2L) which had been approved in the EU since February 2017. In April 2018, Roche Products (Ireland) Ltd submitted a dossier examining the cost-effectiveness of alectinib for the first-line treatment of ALK-positive advanced NSCLC. The authorised dose for this indication

2019 Pediatric Endocrine Society

158. Efficacy of carboplatin plus S-1 (CS) for the treatment of non-small cell lung cancer (NSCLC): a protocol for a systematic review of randomized controlled trials

Efficacy of carboplatin plus S-1 (CS) for the treatment of non-small cell lung cancer (NSCLC): a protocol for a systematic review of randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content

2019 PROSPERO

159. Gender-specific differences in care-seeking behaviour among lung cancer patients: a qualitative systematic literature review

Gender-specific differences in care-seeking behaviour among lung cancer patients: a qualitative systematic literature review Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration record, any

2019 PROSPERO

160. The effect of diabetes mellitus on survival outcomes of patients with non-small cell lung cancer: a systematic review and meta-analysis

The effect of diabetes mellitus on survival outcomes of patients with non-small cell lung cancer: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. The registrant confirms that the information supplied for this submission is accurate and complete. CRD bears no responsibility or liability for the content of this registration

2019 PROSPERO